Plain-English translation of NCT05749588 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a research study testing several different targeted medications for women with advanced triple-negative breast cancer that has stopped responding to standard treatments. The researchers will first analyze your tumor's genetic makeup to determine which medication is most likely to work for you, then treat you with that personalized option. The goal is to find better treatment choices for this difficult-to-treat form of breast cancer.
Triple-negative breast cancer is aggressive and often becomes resistant to standard chemotherapy. This study exists to find new, more effective treatment options by matching each patient's tumor genetics with targeted medications designed to work against those specific genetic changes.
You likely qualify if…
You likely don't qualify if…
After joining, you will have tumor tissue or blood tests to identify your cancer's genetic profile. Based on those results, you will be assigned to receive one of several targeted medications. You will visit the study center for treatment and regular check-ups to monitor how you are responding and to watch for any side effects. The study team will assess your tumor's response using imaging scans and blood tests at scheduled intervals throughout your participation.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China